Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.63 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322456 | 0.98 | UBE2T (0.66) | UBE2TASIC3NPC1RAB9AMAPK1 | |
| SCHEMBL30626888 | 0.98 | UBE2T (0.66) | UBE2TASIC3NPC1RAB9AMAPK1 | |
| Iodide SCHEMBL9450324 | 0.96 | UBE2T (0.63) | UBE2TASIC3NPC1RAB9AMAPK1 | |
| Perchlorate SCHEMBL5072706 | 0.88 | UBE2T (0.54) | UBE2TASIC3NPC1RAB9AMAPK1 | |
| Quinoline SCHEMBL28579596 | 0.85 | ALDH1A1 (0.53) | UBE2TASIC3NPC1RAB9AMAPK1 | |
| Bromide SCHEMBL7601035 | 0.83 | UBE2T (0.68) | UBE2TASIC3NPC1RAB9AMAPK1 | |
| SCHEMBL12511 | 0.82 | UBE2T (0.61) | UBE2TASIC3NPC1RAB9AMAPK1 | |
| SCHEMBL19372016 | 0.81 | UBE2T (0.70) | UBE2TASIC3NPC1RAB9AMAPK1 | |
| SCHEMBL226465 | 0.81 | UBE2T (0.70) | UBE2TASIC3NPC1RAB9AMAPK1 | |
| Hydrogen Sulfide SCHEMBL23045115 | 0.81 | UBE2T (0.59) | UBE2TASIC3NPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110305136-A | A kind of pemetrexed disodium intermediate and preparation method thereof | 鲁南制药集团股份有限公司 | 2019-10-08 | — | — | CN | disclosed |
| CN-110305137-A | A kind of pemetrexed disodium intermediate and preparation method thereof | 鲁南制药集团股份有限公司 | 2019-10-08 | — | — | CN | disclosed |
| US-20100305368-A1 | Combined Formose/Transfer Hydrogenation Process for Ethylene Glycol Synthesis | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2010-12-02 | — | — | US | disclosed |
| WO-2009049114-A1 | A COMBINED FORMOSE/TRANSFER HYDROGENATION PROCESS FOR ETHYLENE GLYCOL SYNTHESIS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008104875-A1 | OXAZOLIDINONES AS CHOLESTEROL ABSORPTION INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| EP-0549886-B1 | Process for the preparation of pyrrolo[2,3-d]pyrimidines | UNIV PRINCETON (US) | 1996-10-30 | — | — | EP | disclosed |
| US-5254687-A | Process for the preparation of pyrrolo[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0549886-A1 | Process for the preparation of pyrrolo[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305368-A1 | Combined Formose/Transfer Hydrogenation Process for Ethylene Glycol Synthesis | GFPT1, INF2, FH | UBE2T 844/4885ASIC3 4638/4885NPC1 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.